Skip to main content

Pharmacopeia Identifies Lead Compound for Bristol-Myers Squibb


PRINCETON, NJ--Pharmacopeia reached a milestone in its collaboration with Bristol-Myers Squibb on inflammatory and immunological disease targets when it identified a lead compound, the company announced last week. Bristol-Myers made a cash payment to Pharmacopeia for the achievement.

In just four months, "using our large, rationally designed libraries of small molecules and high-throughput screening, we were able to identify a lead compound against a challenging target and receive confirmation of activity from Bristol-Myers," Pharmacopeia President Joseph Mollica said.

Pharmacopeia combines small molecule combinatorial chemistry with high-throughput screening for drug discovery. Using a proprietary tagging technology, Eclips, the company generates large libraries of diverse, easily identifiable small molecules. With high-throughput screening, it tests compounds in a full complement of assays, including enzyme, receptor binding, and cell-based assays.

Filed under

The Scan

Not Kept "Clean and Sanitary"

A Food and Drug Administration inspection uncovered problems with cross contamination at an Emergent BioSolutions facility, the Wall Street Journal reports.

Resumption Recommendation Expected

The Washington Post reports that US officials are expected to give the go-ahead to resume using Johnson & Johnson's SARS-CoV-2 vaccine.

Canada's New Budget on Science

Science writes that Canada's new budget includes funding for the life sciences, but not as much as hoped for investigator-driven research.

Nature Papers Examine Single-Cell, Multi-Omic SARS-CoV-2 Response; Flatfish Sequences; More

In Nature this week: single-cell, multi-omics analysis provides insight into COVID-19 pathogenesis, evolution of flatfish, and more.